Immunocompetent murine models for the study of glioblastoma immunotherapy

Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (NEJM 352:987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in clinical outcomes are modest, in no small part due to tumor-induced immunosuppressive mechanisms that promote immune escape and immuno-resistance. Immunotherapeutic strategies aimed at bolstering the immune response while neutralizing immunosuppression will play a critical role in improving treatment outcomes for glioblastoma patients. In vivo murine models of glioma provide an invaluable resource to achieving that end, and their use is an essential part of the preclinical workup for novel therapeutics that need to be tested in animal models prior to testing experimental therapies in patients. In this article, we review five contemporary immunocompetent mouse models, GL261 (C57BL/6), GL26 (C57BL/6) CT-2A (C57BL/6), SMA-560 (VM/Dk), and 4C8 (B6D2F1), each of which offer a suitable platform for testing novel immunotherapeutic approaches.

• Publication year

  2014

• Venue

  Journal of Translational Medicine

• Publication date

  2014-04-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/1479-5876-12-107PMID 24779345PMCID 4012243
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunocompetent murine models for the study of glioblastoma immunotherapy

  2014cited by this paper
• Immunological challenges for peptide-based immunotherapy in glioblastoma.

  2014cited by this paper
• Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells

  2014cited by this paper
• EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss

  2013cited by this paper
• An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma

  2013cited by this paper
• Cell-based immunotherapy against gliomas: from bench to bedside.

  2013cited by this paper
• Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies.

  2013cited by this paper
• Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages

  2013cited by this paper
• Stem-like Tumor-Initiating Cells Isolated from IL13Rα2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine–Redirected T Cells

  2012cited by this paper
• Access to the Nucleus and Functional Association with c-Myc Is Required for the Full Oncogenic Potential of ΔEGFR/EGFRvIII*

  2012cited by this paper
• Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma

  2012cited by this paper
• The Spectrum of Vaccine Therapies for Patients With Glioblastoma Multiforme

  2012cited by this paper
• Preclinical Evaluation of a Genetically Engineered Herpes Simplex Virus Expressing Interleukin-12

  2012cited by this paper
• Stemness of the CT-2A Immunocompetent Mouse Brain Tumor Model: Characterization In Vitro

  2012influential reference
• Capturing the Molecular and Biological Diversity of High-Grade Astrocytoma in Genetically Engineered Mouse Models

  2012cited by this paper
• Insights gained from modelling high‐grade glioma in the mouse

  2012cited by this paper
• Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.

  2012cited by this paper
• Cancer immunotherapy comes of age.

  2011cited by this paper
• The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-β2.

  2011cited by this paper
• Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

  2011cited by this paper
• Genetic modeling of gliomas in mice: New tools to tackle old problems

  2011cited by this paper
• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011cited by this paper
• Cancer immunotherapy comes of age

  2011cited by this paper
• Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model

  2011cited by this paper
• Mesenchymal Stem Cells Modified with a Single-Chain Antibody against EGFRvIII Successfully Inhibit the Growth of Human Xenograft Malignant Glioma

  2010cited by this paper
• A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion

  2010cited by this paper
• Retrovirally engineered T‐cell‐based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma‐associated antigen

  2010cited by this paper
• HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors

  2010cited by this paper
• Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma.

  2010cited by this paper
• Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma.

  2010cited by this paper
• Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies

  2010cited by this paper
• Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties.

  2010cited by this paper
• Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression

  2010cited by this paper
• Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway

  2010cited by this paper
• The Murine GL261 Glioma Experimental Model to Assess Novel Brain Tumor Treatments

  2009cited by this paper
• Systemic Inhibition of Transforming Growth Factor-β in Glioma-Bearing Mice Improves the Therapeutic Efficacy of Glioma-Associated Antigen Peptide Vaccines

  2009cited by this paper
• Honokiol-mediated Inhibition of PI3K/mTOR Pathway: A Potential Strategy to Overcome Immunoresistance in Glioma, Breast, and Prostate Carcinoma Without Impacting T Cell Function

  2009cited by this paper
• DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.

  2009cited by this paper
• Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas

  2009cited by this paper
• Immunological Factors Relating to the Antitumor Effect of Temozolomide Chemoimmunotherapy in a Murine Glioma Model

  2009cited by this paper
• Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting

  2009cited by this paper
• Isolation and characterization of cancer stem like cells in human glioblastoma cell lines.

  2009cited by this paper
• Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma.

  2009cited by this paper
• An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

  2009cited by this paper
• Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.

  2008cited by this paper
• Akt-Dependent Proapoptotic Effects of Dietary Restriction on Late-Stage Management of a Phosphatase and Tensin Homologue/Tuberous Sclerosis Complex 2–Deficient Mouse Astrocytoma

  2008cited by this paper
• Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

  2008cited by this paper
• Persistence of CD133+ Cells in Human and Mouse Glioma Cell Lines: Detailed Characterization of GL261 Glioma Cells with Cancer Stem Cell-Like Properties

  2008cited by this paper
• A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma.

  2008cited by this paper
• Identification of cells initiating human melanomas

  2008cited by this paper
• CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers

  2008cited by this paper
• Genetically Engineered Mouse Models of Brain Cancer and the Promise of Preclinical Testing

  2008cited by this paper
• Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme

  2008cited by this paper
• Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients

  2008cited by this paper
• Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical Trials

  2008cited by this paper
• Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies.

  2007influential reference
• Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts.

  2007cited by this paper
• Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function

  2007influential reference
• Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia.

  2007cited by this paper
• Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy

  2007cited by this paper
• Standardization of an orthotopic mouse brain tumor model following transplantation of CT-2A astrocytoma cells.

  2007influential reference
• Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

  2007cited by this paper
• Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression

  2007cited by this paper
• Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model.

  2007cited by this paper
• LACK OF B7 EXPRESSION, NOT HUMAN LEUKOCYTE ANTIGEN EXPRESSION, FACILITATES IMMUNE EVASION BY HUMAN MALIGNANT GLIOMAS

  2007cited by this paper
• Emerging role of new transgenic mouse models in glioma research

  2007cited by this paper
• Inhibition of TGF-β2 with AP 12009 in Recurrent Malignant Gliomas: From Preclinical to Phase I/II Studies

  2007cited by this paper
• Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice

  2006cited by this paper
• Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas.

  2006cited by this paper
• Targeting of CD44 eradicates human acute myeloid leukemic stem cells

  2006cited by this paper
• Chemotherapy resistance of glioblastoma stem cells

  2006cited by this paper
• Expression of MHC I and NK ligands on human CD133 + glioma cells: possible targets of immunotherapy

  2006cited by this paper
• Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas

  2006cited by this paper
• Gene‐linked shift in ganglioside distribution influences growth and vascularity in a mouse astrocytoma

  2006cited by this paper
• Requirement for CD44 in homing and engraftment of BCR-ABL–expressing leukemic stem cells

  2006cited by this paper
• Identification of a glioma antigen, GARC‐1, using cytotoxic T lymphocytes induced by HSV cancer vaccine

  2006cited by this paper
• Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.

  2006cited by this paper
• Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy

  2006influential reference
• Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12

  2006cited by this paper
• Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo

  2005cited by this paper
• Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.

  2005cited by this paper
• Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain

  2005cited by this paper
• Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Delivery of Dendritic Cells Engineered to Secrete IFN-α into Central Nervous System Tumors Enhances the Efficacy of Peripheral Tumor Cell Vaccines: Dependence on Apoptotic Pathways1

  2005cited by this paper
• Immunization with Dendritic Cells Pulsed with Tumor Extract Increases Survival of Mice Bearing Intracranial Gliomas

  2004cited by this paper
• Antiangiogenic and Proapoptotic Effects of Dietary Restriction on Experimental Mouse and Human Brain Tumors

  2004cited by this paper
• Identification of human brain tumour initiating cells

  2004cited by this paper
• Isolation of cancer stem cells from adult glioblastoma multiforme

  2004cited by this paper
• Growth inhibition of an orthotopic glioblastoma in immunocompetent mice by cationic lipid-DNA complexes

  2004cited by this paper
• A Combination of flk1-Based DNA Vaccine and an Immunomodulatory Gene (IL-12) in the Treatment of Murine Cancer

  2004cited by this paper
• Spontaneous regression of experimental gliomas--an immunohistochemical and MRI study of the C6 glioma spheroid implantation model.

  2004cited by this paper
• Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA)

  2004cited by this paper
• SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo

  2004cited by this paper
• Sequential delivery of interferon-α gene and DCs to intracranial gliomas promotes an effective antitumor response

  2004cited by this paper
• PI3K/Akt signalling pathway and cancer.

  2004cited by this paper
• Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors

  2004cited by this paper
• Vaccination with tumor cell lysate‐pulsed dendritic cells augments the effect of IFN‐β gene therapy for malignant glioma in an experimental mouse intracranial glioma

  2004cited by this paper
• Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.

  2003cited by this paper
• Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.

  2003cited by this paper

• A novel murine model of LITT for glioblastoma reveals tumor reduction, BBB permeabilization, and drug delivery via ThermoDox®.

  2026cites this paper
• Functional HER1/HER2-Expressing Murine Tumor Models for Preclinical Evaluation of Targeted Therapies

  2025cites this paper
• Disrupting Akt-Wnt/β-catenin signaling suppresses glioblastoma stem cell growth and tumor progression in immunocompetent mice

  2025cites this paper
• Efficacy of Oncolytic Virus VV-GMCSF-Lact Against Immunocompetent Glioma

  2025cites this paper
• IL-7–mediated expansion of autologous lymphocytes increases CD8+ VLA-4 expression and accumulation in glioblastoma models

  2025cites this paper
• Folic Acid-Decorated Lipidic Nanocapsules Co-Loaded with Atorvastatin and Curcumin to Enhance Glioma Targeting in Mice

  2025cites this paper
• APOE Drives Glioma Progression by Modulating CCL5/CCR5 Signaling in the Tumor Microenvironment and Inducing M2 Macrophage Polarization.

  2025cites this paper
• Wnt inhibition alleviates resistance to anti-PD1 therapy and improves antitumor immunity in glioblastoma

  2025cites this paper
• Targeting TGFβ docking receptor Glycoprotein A Repetitions Predominant (GARP) via novel chimeric antigen receptor (CAR)-T cell platform to treat glioblastoma.

  2025cites this paper
• Combining the RCAS/tv-a retrovirus and CRISPR/Cas9 gene editing systems to generate primary mouse models of diffuse midline glioma

  2025cites this paper
• Targeting cIAP2 in a novel senolytic strategy prevents glioblastoma recurrence after radiotherapy

  2025cites this paper
• In vivo generation of CAR macrophages via the enucleated mesenchymal stem cell delivery system for glioblastoma therapy

  2025cites this paper
• 7aaRGD - a novel SPP1/integrin signaling-blocking peptide reverses immunosuppression and improves anti-PD-1 immunotherapy outcomes in experimental gliomas

  2025cites this paper
• Loss of LAPTM4A inhibits M2 polarization of tumor-associated macrophages in glioblastoma, promoting immune activation and enhancing anti-PD1 therapy

  2025cites this paper
• Novel Taxol-Derivative, STO-1, Induces Selective Anti-Tumor Immunity and Sustained Remission of Glioblastoma Without Triggering Autoimmune Reactions

  2025cites this paper
• Impact of celastrol on mitochondrial dynamics and proliferation in glioblastoma

  2025cites this paper
• Syngeneic Mouse Model of Glioblastoma: Intracranial Implantation of GL261 Cells.

  2024cites this paper
• Arming AAV9 with a Single-Chain Fragment Variable Antibody Against PD-1 for Systemic Glioblastoma Therapy

  2024cites this paper
• TLR agonists promote formation of Tertiary Lymphoid Structure and improve anti-glioma immunity.

  2024cites this paper
• V‐domain immunoglobulin suppressor of T‐cell activation and programmed death receptor 1 dual checkpoint blockade enhances antitumour immunity and survival in glioblastoma

  2024cites this paper
• PTP4A2 Promotes Glioblastoma Progression and Macrophage Polarization under Microenvironmental Pressure

  2024cites this paper
• Pulsed focused ultrasound alters the proteomic profile of the tumor microenvironment in a syngeneic mouse model of glioblastoma

  2024cites this paper
• The Immunomodulatory Effects of Fluorescein-Mediated Sonodynamic Treatment Lead to Systemic and Intratumoral Depletion of Myeloid-Derived Suppressor Cells in a Preclinical Malignant Glioma Model

  2024cites this paper
• Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival

  2024cites this paper
• Deuterium metabolic imaging phenotypes mouse glioblastoma heterogeneity through glucose turnover kinetics

  2024cites this paper
• Machine Learning-Directed Conversion of Glioblastoma Cells to Dendritic Cell-like Antigen-Presenting Cells as Cancer Immunotherapy.

  2024cites this paper
• [89Zr]-CD8 ImmunoPET imaging of glioblastoma multiforme response to combination oncolytic viral and checkpoint inhibitor immunotherapy reveals CD8 infiltration differential changes in preclinical models

  2024cites this paper
• KR158 Spheres Harboring Slow-Cycling Cells Recapitulate High-Grade Glioma Features in an Immunocompetent System

  2024cites this paper
• All-trans retinoic acid inhibits glioblastoma progression and attenuates radiation-induced brain injury

  2024cites this paper
• Role of scaffold proteins in the heterogeneity of glioblastoma

  2024cites this paper
• MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppression

  2024cites this paper
• Bridging the gap between tumor and disease: Innovating cancer and glioma models

  2024cites this paper
• Nanosponges in Therapeutics: Current Advancements and Future Directions in Targeted Drug Delivery

  2024cites this paper
• Polio Virotherapy Targets the Malignant Glioma Myeloid Infiltrate with Diffuse Microglia Activation Engulfing the CNS.

  2023cites this paper
• STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma

  2023cites this paper
• Distinct spatiotemporal features of microglia and monocyte‐derived macrophages in glioma

  2023cites this paper
• Preclinical Experimental Models for Human Glioma

  2023cites this paper
• Mismatch between Bioluminescence Imaging (BLI) and MRI When Evaluating Glioblastoma Growth: Lessons from a Study Where BLI Suggested “Regression” while MRI Showed “Progression”

  2023cites this paper
• Pre-clinical models for evaluating glioma targeted immunotherapies

  2023cites this paper
• In vivo C6 glioma models: an update and a guide toward a more effective preclinical evaluation of potential anti-glioblastoma drugs

  2023cites this paper
• Translational Models in Glioma Immunotherapy Research

  2023cites this paper
• Wnt inhibition alleviates resistance to immune checkpoint blockade in glioblastoma

  2023cites this paper
• Limited Effects of Class II Transactivator-Based Immunotherapy in Murine and Human Glioblastoma

  2023cites this paper
• CTLA-4 blockade induces CD4+ T cell IFNγ-driven microglial phagocytosis and anti-tumor function in glioblastoma.

  2023cites this paper
• Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression.

  2023cites this paper
• CAR T-cell Design-dependent Remodeling of the Brain Tumor Immune Microenvironment Modulates Tumor-associated Macrophages and Anti-glioma Activity

  2023cites this paper
• Expression of intra-tumoral necrosis-associated cytokine pattern correlated with prognosis and immune status in glioma

  2023cites this paper
• Efficacy of combined tumor irradiation and KCa3.1-targeting with TRAM-34 in a syngeneic glioma mouse model

  2023cites this paper
• Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction

  2023cites this paper
• Preclinical Models and Technologies in Glioblastoma Research: Evolution, Current State, and Future Avenues

  2023cites this paper
• The Blood-Brain Barrier: Implications for Experimental Cancer Therapeutics

  2023cites this paper
• Protocol to analyze antitumor immunity of orthotopic injection and spontaneous murine high-grade glioma models using flow cytometry and single-cell RNA sequencing

  2022cites this paper
• Glucose fluxes in glycolytic and oxidative pathways detected in vivo by deuterium magnetic resonance spectroscopy reflect proliferation in mouse glioblastoma

  2022cites this paper
• A microglia-CD4+ T cell partnership generates protective anti-tumor immunity to glioblastoma

  2022cites this paper
• Endothelial EphrinB2 Regulates Sunitinib Therapy Response in Murine Glioma

  2022cites this paper
• Elucidating tumour‐associated microglia/macrophage diversity along glioblastoma progression and under ACOD1 deficiency

  2022cites this paper
• In vivo Deuterium Magnetic Resonance Spectroscopy reveals Glucose fluxes through glycolysis and mitochondrial oxidation pathways in mouse Glioblastoma

  2022cites this paper
• Rat and Mouse Brain Tumor Models for Experimental Neuro-Oncology Research

  2022cites this paper
• Guidelines for DC preparation and flow cytometry analysis of mouse nonlymphoid tissues

  2022cites this paper
• Polio Virotherapy of Malignant Glioma Engages the Tumor Myeloid Infiltrate and Induces Diffuse Microglia Activation

  2022cites this paper
• Establishing Imaging Biomarkers of Host Immune System Efficacy during Glioblastoma Therapy Response: Challenges, Obstacles and Future Perspectives

  2022cites this paper
• Short TE downfield magnetic resonance spectroscopy in a mouse model of brain glioma

  2022cites this paper
• Tumor-Associated Macrophages in Gliomas—Basic Insights and Treatment Opportunities

  2022cites this paper
• LPPR5 Expression in Glioma Affects Growth, Vascular Architecture, and Sunitinib Resistance

  2022cites this paper
• Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma

  2022cites this paper
• Syngeneic murine glioblastoma models: reactionary immune changes and immunotherapy intervention outcomes.

  2022influential citation
• Therapeutic intervention of glioma with the novel antineoplastic agent T11TS: the story so far.

  2022cites this paper
• Combined blockade of VEGF, Angiopoietin-2, and PD1 reprograms glioblastoma endothelial cells into quasi-antigen-presenting cells

  2022cites this paper
• Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword

  2022cites this paper
• Physical Training Protects Against Brain Toxicity in Mice Exposed to an Experimental Model of Glioblastoma

  2022influential citation
• Myeloid cell interferon secretion restricts Zika flavivirus infection of developing and malignant human neural progenitor cells

  2022cites this paper
• Long-acting recombinant human interleukin-7, NT-I7, increases cytotoxic CD8+ T cells and enhances survival in mouse glioma models.

  2022cites this paper
• Spatial patterning and immunosuppression of glioblastoma immune contexture in hypoxic niches

  2022cites this paper
• Mesenchymal Stem Cell-mediated Image-guided Sodium Iodide Symporter (NIS) Gene Therapy Improves Survival of Glioblastoma-bearing Mice.

  2022cites this paper
• Translation of focused ultrasound for blood-brain barrier opening in glioma.

  2022cites this paper
• Differential effects of radiation fractionation regimens on glioblastoma

  2022cites this paper
• Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma

  2022cites this paper
• Elimination of Radiation-Induced Senescence in the Brain Tumor Microenvironment Attenuates Glioblastoma Recurrence

  2021influential citation
• Myeloid-derived suppressor cells (MDSCs) in brain cancer: challenges and therapeutic strategies

  2021cites this paper
• The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment

  2021cites this paper
• Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment

  2021cites this paper
• Preclinical models and technologies to advance nanovaccine development.

  2021cites this paper
• OV_A_268426 1..27

  2021cites this paper
• Rodent Brain Tumor Models for Neuro-Oncology Research

  2021cites this paper
• Preclinical Solid Tumor Models to Study Novel Therapeutics in Brain Metastases

  2021cites this paper
• Technical choices significantly alter the adaptive immune response against immunocompetent murine gliomas in a model-dependent manner

  2021cites this paper
• Mouse models of glioblastoma for the evaluation of novel therapeutic strategies

  2021cites this paper
• Argyrin F Treatment‐Induced Vulnerabilities Lead to a Novel Combination Therapy in Experimental Glioma

  2021cites this paper
• Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma

  2021influential citation
• PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of Glioblastoma.

  2021cites this paper
• Mouse Models of Experimental Glioblastoma

  2021cites this paper
• Glycolysis and Fatty Acid Oxidation Inhibition Improves Survival in Glioblastoma

  2021cites this paper
• Reversing Epigenetic Gene Silencing to Overcome Immune Evasion in CNS Malignancies

  2021cites this paper
• Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages

  2021cites this paper
• Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells

  2021cites this paper
• Leveraging the replication‐competent avian‐like sarcoma virus/tumor virus receptor‐A system for modeling human gliomas

  2021cites this paper
• Synergy between glutamate modulation and anti-programmed cell death protein 1 immunotherapy for glioblastoma.

  2021cites this paper
• DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies

  2021cites this paper
• Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma

  2021cites this paper
• Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET

  2021cites this paper